{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T02:26:52Z","timestamp":1743733612980},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Doctoral Fund of the Ministry of Education","award":["20120181110008"],"award-info":[{"award-number":["20120181110008"]}]},{"name":"Foundation of the Science & Technology Department of Sichuan Province","award":["2013SZ0025"],"award-info":[{"award-number":["2013SZ0025"]}]},{"name":"Foundation of Traditional Chinese Medicine Bureau of Sichuan Province","award":["2014A03"],"award-info":[{"award-number":["2014A03"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.leukres.2016.01.007","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T11:46:34Z","timestamp":1452944794000},"page":"59-67","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15\/RI"],"prefix":"10.1016","volume":"42","author":[{"given":"Duolan","family":"Naren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyou","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.01.007_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.01.007_bib0010","first-page":"596483","article-title":"Therapy of chronic myeloid leukemia: twilight of the imatinibera?","volume":"2014","author":"Trela","year":"2014","journal-title":"ISRN Oncol."},{"key":"10.1016\/j.leukres.2016.01.007_bib0015","first-page":"10","article-title":"New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure","volume":"69","author":"Thielen","year":"2011","journal-title":"Neth. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2016.01.007_bib0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2016.01.007_bib0025","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2016.01.007_bib0030","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug transporters and imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2016.01.007_bib0035","first-page":"4","article-title":"Multidrug resistant gene MDR1 contributes to development of imatinib-resistance in Ph (+) acute lymphoblastic leukemia cell line SUP-BS15RI","volume":"43","author":"Lin","year":"2012","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.leukres.2016.01.007_bib0040","unstructured":"Patterson M.C., Vanier M.T., Suzuki K., Morris J.A., Carstea E., Neufeld E.B. et al. The Metabolic and Molecular Bases of Inherited Disease 8th Ed. (2001) 3 23."},{"issue":"22","key":"10.1016\/j.leukres.2016.01.007_bib0045","doi-asserted-by":"crossref","first-page":"20917","DOI":"10.1074\/jbc.R400040200","article-title":"Niemann-Pick type C disease and intracellular cholesterol trafficking","volume":"280","author":"Chang","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.leukres.2016.01.007_bib0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cmet.2010.05.016","article-title":"Identification of surface residues on Niemann-Pick C2 essential for hydrophobic handoff of cholesterol to NPC1 in lysosomes","volume":"12","author":"Wang","year":"2010","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.leukres.2016.01.007_bib0055","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1074\/jbc.M707944200","article-title":"Purified NPC1 protein: II: localization of sterol binding to a 240-amino acid soluble luminal loop","volume":"283","author":"Infante","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2016.01.007_bib0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1126\/science.290.5500.2295","article-title":"Transmembrane molecular pump activity of Niemann-Pick C1 protein","volume":"290","author":"Davies","year":"2000","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.leukres.2016.01.007_bib0065","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1124\/jpet.105.089482","article-title":"Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway","volume":"316","author":"Gong","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"24","key":"10.1016\/j.leukres.2016.01.007_bib0070","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.leukres.2016.01.007_bib0075","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol. Cell. Biol."},{"issue":"20","key":"10.1016\/j.leukres.2016.01.007_bib0080","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2016.01.007_bib0085","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2016.01.007_bib0090","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.leukres.2016.01.007_bib0095","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.01.007_bib0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.leukres.2016.01.007_bib0105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2016.01.007_bib0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.leukres.2016.01.007_bib0115","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1161\/01.ATV.0000131264.66417.d5","article-title":"Intracellular cholesterol transport","volume":"24","author":"Soccio","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.leukres.2016.01.007_bib0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0828-282X(06)70985-0","article-title":"Cellular cholesterol homeostasis in vascular endothelial cells","volume":"22","author":"Hassan","year":"2006","journal-title":"Can. J. Cardiol."},{"issue":"1","key":"10.1016\/j.leukres.2016.01.007_bib0125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.plipres.2012.11.002","article-title":"Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis","volume":"52","author":"Musso","year":"2013","journal-title":"Prog. Lipid Res."},{"issue":"1","key":"10.1016\/j.leukres.2016.01.007_bib0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2013.02.033","article-title":"Interrelationship between ATP-binding cassette transporters and oxysterols","volume":"86","author":"Ruiz","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.leukres.2016.01.007_bib0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbrc.2015.01.045","article-title":"ABCB1, ABCC1, and LRP gene expressions are altered by LDL, HDL, and serum deprivation in a human doxorubicin-resistant uterine sarcoma cell line","volume":"457","author":"Celestino","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9\u201310","key":"10.1016\/j.leukres.2016.01.007_bib0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","article-title":"The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)","volume":"13","author":"Szakacs","year":"2008","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.leukres.2016.01.007_bib0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.exphem.2007.07.017","article-title":"P-Glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors","volume":"35","author":"Connelly-Smith","year":"2007","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2016.01.007_bib0150","first-page":"10","article-title":"Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease","volume":"53","author":"Hungria","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.leukres.2016.01.007_bib0155","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1006\/bbrc.2000.3554","article-title":"Cholesterol interaction with the daunorubicin binding site of P-glycoprotein","volume":"276","author":"Wang","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"13","key":"10.1016\/j.leukres.2016.01.007_bib0160","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1016\/j.febslet.2010.04.047","article-title":"Defective cholesterol trafficking in Niemann-Pick C-deficient cells","volume":"584","author":"Peake","year":"2010","journal-title":"FEBS Lett."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T20:17:49Z","timestamp":1656188269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616300078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":32,"alternative-id":["S0145212616300078"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.01.007","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15\/RI","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}